Objective  To explore the potential molecular mechanism of Moluodan concentrated pill (MLD) in the treatment of chronic atrophic gastritis (CAG).

Methods  The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Traditional Chinese Medicine Integrated Database (TCMID), Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine (TCMIP), and Traditional Chinese Medicine on Immuno-Oncology (TCMIO) were used to obtain the compounds of MLD and compound-related targets (CRTs). DisGeNET and GeneCards databases were used to obtain CAG related target genes (CAG-RTGs). The MLD compound-CRT network was constructed using Cytoscape 3.7.2 software, and the intersection of CRTs and CAG-RTGs was taken to obtain MLD-related disease targets (MLD-RDTs). The STRING database was used to construct the protein-protein interaction (PPI) network of MLD-RDTs and perform topological structure analysis to screen for important targets. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis were used to explore the main molecular mechanism of MLD in the treatment of CAG.

Results  A total of 259 active molecules in MLD obtained 961 target genes, of which 179 may be related to CAG. The PPI network showed that AKT1, TNF, IL-6, TP53, IL-1β, etc. were the key targets of MLD in the treatment of CAG. Enrichment analysis showed that the key pathways of MLD in the treatment of CAG were the PI3K-AKT signaling pathway and the TNF signaling pathway.

Conclusion  MLD may treat CAG by mediating the TNF/PI3K/AKT signaling pathway.

1.Li X, Feng M, Yuan G. Clinical efficacy of Weisu granule combined with Weifuchun tablet in the treatment of chronic atrophic gastritis and its effect on serum G-17, PG I and PG II levels[J]. Am J Transl Res, 2022, 14(1): 275-284. https://pubmed.ncbi.nlm.nih.gov/35173844/

2.Zhou W, Zhang H, Wang X, et al. Network pharmacology to unveil the mechanism of Moluodan in the treatment of chronic atrophic gastritis[J]. Phytomedicine, 2022, 95: 153837. DOI: 10.1016/j.phymed.2021.153837.

3.Pei B, Wen Z, Yang Q, et al. Risk factors analysis and prediction model establishment of intestinal metaplasia or dysplasia in patients with chronic atrophic gastritis: a multi-center retrospective study[J]. Front Med (Lausanne), 2022, 9: 912331. DOI: 10.3389/fmed.2022.912331.

4.Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019[J]. Endoscopy, 2019, 51(4): 365-388. DOI: 10.1055/a-0859-1883.

5.Yin Y, Li H, Feng J, et al. Prevalence and clinical and endoscopic characteristics of cervical inlet patch (heterotopic gastric mucosa): a systematic review and Meta-analysis[J]. J Clin Gastroenterol, 2022, 56(3): e250-e262. DOI: 10.1097/MCG.0000000000001516.

6.Yan ZX, Dai YK, Ma T, et al. Efficacy of traditional Chinese medicine for chronic gastritis: a meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2019, 98(20): e15710. DOI: 10.1097/MD.0000000000015710.

7.Tang XD, Zhou LY, Zhang ST, et al. Randomized double-blind clinical trial of Moluodan for the treatment of chronic atrophic gastritis with dysplasia[J]. Chin J Integr Med, 2016, 22(1): 9-18. DOI: 10.1007/s11655-015-2114-5.

8.殷苗苗, 睢建亮, 王梦蕾, 等. 摩罗丹浓缩丸治疗慢性萎缩性胃炎的药效及作用机制[J]. 现代中医药, 2024, 44(2): 98-109. [Yin MM, Sui JL, Wang ML, et al. Morodan concentrated pills for the treatment of chronic atrophic gastritis and its mechanism of action[J]. Modern Traditional Chinese Medicine, 2024, 44(2): 98-109.] DOI: 10.13424/j.cnki.mtcm.2024.02.018.

9.《中成药治疗优势病种临床应用指南》标准化项目组. 中成药治疗慢性胃炎临床应用指南（2020 年） [J]. 中国中西医结合杂志, 2021, 41(2): 157-163. [Standardized Project Team of Clinical Application Guidelines of Chinese Patent Medicine in the Treatment of Dominant Diseases. Clinical application guidelines of Chinese patent medicine in the treatment for chronic gastritis (2020)[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2021, 41(2): 157-163.] DOI: 10.7661/j.cjim.20210125.005.

10.杜爱民, 杨霞, 刘杰, 等. 摩罗丹与叶酸联合维生素E治疗慢性萎缩性胃炎的对比研究[J]. 中医药临床杂志, 2015, 27(12): 1717-1720. [Du AM, Yang X, Liu J, et al. A comparison of the treatment to the chronic atrophic gastritis by the folic acid combined with vitamin E and by Mo Luo Dan[J]. Clinical Journal of Traditional Chinese Medicine, 2015, 27(12): 1717-1720.] DOI: 10.16448/j.cjtcm.2015.0636.

11.刘绍能, 刘正新, 孟淼, 等. 摩罗丹配合雷贝拉唑三联疗法治疗幽门螺杆菌相关慢性胃炎疗效观察[J]. 现代中西医结合杂志, 2017, 26(7): 749-751. [Liu SN, Liu ZX, Meng M, et al. Efficacy of Moradan combined with rabeprazole triple therapy in treating Helicobacter pylori-related chronic gastritis[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2017, 26(7): 749-751.] DOI: 10.3969/j.issn.1008-8849.2017.07.023.

12.Hopkins AL. Network pharmacology: the next paradigm in drug discovery[J]. Nature chemical biology, 2008, 11(4): 682-690. DOI: 10.1038/nchembio.118.

13.马林, 唐纯志, 章小梅. 埋线对慢性萎缩性胃炎模型组大鼠胃泌素-17、血管内皮生长因子、肿瘤坏死因子-α表达的影响[J]. 辽宁中医杂志, 2020, 47(12): 168-170. [Ma L, Tang CZ, Zhang XM. Effect of embedding thread on expressions of gastrin-17, VEGF and TNF-α in chronic atrophic gastritis model rats[J]. Liaoning Journal of Traditional Chinese Medicine, 2020, 47(12): 168-170.] DOI: 10.13192/j.issn.1000-1719.2020.12.049.

14.El-Omar EM. Role of host genes in sporadic gastric cancer[J]. Best Pract Res Clin Gastroenterol, 2006, 20(4): 675-686. DOI: 10.1016/j.bpg.2006.04.006.

15.佘荣荣, 郭金伟, 葛惠男. 益气活血通络方加减对气虚血瘀型慢性萎缩性胃炎患者胃黏膜PTEN及血清IL-6、TNF-α的影响[J]. 浙江中医药大学学报, 2023, 47(1): 52-57. [She RR, Guo JW, Ge HN. Effect of Yiqi Huoxue Tongluo Recipe on PTEN in gastric mucosa and serum IL-6 and TNF-α of patients with chronic atrophic gastritis of Qi deficiency and blood stasis type[J]. Journal of Zhejiang Chinese Medical University, 2023, 47(1): 52-57.] DOI: 10.16466/j.issn1005-5509.2023.01.011.

16.Crabtree JE, Shallcross TM, Heatley RV, et al. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis[J]. Gut, 1991, 32(12): 1473-1477. DOI: 10.1136/gut.32.12.1473.

17.Ota M, Tahara T, Otsuka T, et al. Association between receptor interacting serine/threonine kinase 2 polymorphisms and gastric cancer susceptibility[J]. Oncol Lett, 2018, 15(3): 3772-3778. DOI: 10.3892/ol.2018.7785.

18.向阳, 黄琼, 袁林. 黄连半夏药对治疗慢性萎缩性胃炎作用机制研究[J]. 天然产物研究与开发, 2022, 34(11): 1822-1831. [Xiang Y, Huang Q, Yuan L. Study on the mechanism of action on the treatment of chronic atrophic gastritis[J]. Natural Product Research and Development, 2022, 34(11): 1822-1831.] DOI: 10.16333/j.1001-6880.2022.11.002.

19.Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review[J]. Gastroenterology, 2021, 161(4): 1325-1332.e7. DOI: 10.1053/j.gastro.2021.06.078.

20.Oshima H, Ishikawa T, Yoshida GJ, et al. TNF-α/TNFR1 signaling promotes gastric tumorigenesis through induction of Noxo1 and Gna14 in tumor cells[J]. Oncogene, 2014, 33(29): 3820-3829. DOI: 10.1038/onc.2013.356.

21.Villegas SN, Gombos R, García-López L, et al. PI3K/Akt cooperates with oncogenic notch by inducing nitric oxide-dependent inflammation[J]. Cell Rep, 2018, 22(10): 2541-2549. DOI: 10.1016/j.celrep.2018.02.049.